Literature DB >> 18521443

Soft tissue and bone sarcoma group, 25th anniversary meeting on sarcomas, april 5-7, 2001, aarhus, denmark.

J Gibbs1.   

Abstract

Entities:  

Year:  2001        PMID： 18521443      PMCID： PMC2408367          DOI： 10.1080/135771401200XXXXX

Source DB:  PubMed          Journal:  Sarcoma        ISSN： 1357-714X


× No keyword cloud information.
  21 in total

1.  Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.

Authors:  M Van Glabbeke; A T van Oosterom; J W Oosterhuis; H Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz
Journal:  J Clin Oncol       Date:  1999-01       Impact factor: 44.544

2.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

Authors:  D Lienard; P Ewalenko; J J Delmotte; N Renard; F J Lejeune
Journal:  J Clin Oncol       Date:  1992-01       Impact factor: 44.544

3.  (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma.

Authors:  A L Folpe; R H Lyles; J T Sprouse; E U Conrad; J F Eary
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

4.  A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations.

Authors:  F Gherlinzoni; G Bacci; P Picci; R Capanna; P Calderoni; E G Lorenzi; M Bernini; E Emiliani; E Barbieri; A Normand
Journal:  J Clin Oncol       Date:  1986-04       Impact factor: 44.544

5.  Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group.

Authors:  T A Alvegård; H Sigurdsson; H Mouridsen; O Solheim; B Unsgaard; U Ringborg; O Dahl; A M Nordentoft; C Blomqvist; A Rydholm
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

6.  Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group.

Authors:  A Le Cesne; I Judson; D Crowther; S Rodenhuis; H J Keizer; Q Van Hoesel; J Y Blay; J Frisch; M Van Glabbeke; C Hermans; A Van Oosterom; T Tursz; J Verweij
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

7.  Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.

Authors:  F J Lejeune; N Pujol; D Liénard; F Mosimann; W Raffoul; A Genton; L Guillou; M Landry; P G Chassot; R Chiolero; A Bischof-Delaloye; S Leyvraz; R O Mirimanoff; D Bejkos; P F Leyvraz
Journal:  Eur J Surg Oncol       Date:  2000-11       Impact factor: 4.424

8.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.

Authors:  G A Omura; J A Blessing; F Major; S Lifshitz; C E Ehrlich; C Mangan; J Beecham; R Park; S Silverberg
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

Review 9.  Clinical applications of TNF-alpha in cancer.

Authors:  F J Lejeune; C Rüegg; D Liénard
Journal:  Curr Opin Immunol       Date:  1998-10       Impact factor: 7.486

10.  A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk.

Authors:  J Glenn; T Kinsella; E Glatstein; J Tepper; A Baker; P Sugarbaker; W Sindelar; J Roth; M Brennan; J Costa
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.